Schedule 13D ownership disclosure

THERAVANCE BIOPHARMA INC

Security class unavailable · CUSIP: G8807B106

Event date: 2020-02-10

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
9,644,808
Percent of class
15.5000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001387131-20-002259
Form type
SC 13D/A
Filer
GSK plc
CIK
CIK 1131399
Filed
Feb 27, 2020
Reporting period
Feb 10, 2020
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub